All In MedTech

Device Trial Radar · NCT04795635

Axon Therapy for Post-Traumatic Peripheral Neuropathic Pain Compared to Conventional Medical Management

A Prospective, Randomized, Clinical Trial Comparing the Safety and Effectiveness of Axon Therapy for Post-Traumatic Peripheral Neuropathic Pain (PTPNP) to Conventional Medical Management (CMM)

Last checked: Nov 20, 2026Latest source record: Jul 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

61

Actual

Start

Apr 14, 2021

Primary completion

May 22, 2024

Study completion Aug 22, 2024

Sponsor

Lead sponsor
NeuraLace Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 12, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Compare Axon Therapy using transcutaneous magnetic stimulation (tMS) against conventional medical management in treating post-traumatic peripheral neuropathic pain (PTPNP).

Conditions

  • Neuropathic Pain
  • Peripheral Neuropathy

Interventions

  • CMM + Axon TherapyDevice

    transcutaneous magnetic stimulation (tMS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the Proportion of RespondersTime frame: 90 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • National Spine and Pain Centers

    Shrewsbury, New Jersey

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.